Managing cardiotoxicity associated with immune checkpoint inhibitors

Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are availabl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sireesha Upadhrasta, Hadi Elias, Keval Patel, Lei Zheng
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b91444971101405b80c7c7722ba90885
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b91444971101405b80c7c7722ba90885
record_format	dspace
spelling	oai:doaj.org-article:b91444971101405b80c7c7722ba908852021-12-02T16:42:39ZManaging cardiotoxicity associated with immune checkpoint inhibitors2095-882X10.1016/j.cdtm.2019.02.004https://doaj.org/article/b91444971101405b80c7c7722ba908852019-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18301117https://doaj.org/toc/2095-882XImmuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, PembrolizumabSireesha UpadhrastaHadi EliasKeval PatelLei ZhengKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 1, Pp 6-14 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng Managing cardiotoxicity associated with immune checkpoint inhibitors
description	Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, Pembrolizumab
format	article
author	Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng
author_facet	Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng
author_sort	Sireesha Upadhrasta
title	Managing cardiotoxicity associated with immune checkpoint inhibitors
title_short	Managing cardiotoxicity associated with immune checkpoint inhibitors
title_full	Managing cardiotoxicity associated with immune checkpoint inhibitors
title_fullStr	Managing cardiotoxicity associated with immune checkpoint inhibitors
title_full_unstemmed	Managing cardiotoxicity associated with immune checkpoint inhibitors
title_sort	managing cardiotoxicity associated with immune checkpoint inhibitors
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/b91444971101405b80c7c7722ba90885
work_keys_str_mv	AT sireeshaupadhrasta managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT hadielias managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT kevalpatel managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT leizheng managingcardiotoxicityassociatedwithimmunecheckpointinhibitors
_version_	1718383535956426752

Managing cardiotoxicity associated with immune checkpoint inhibitors

Ejemplares similares